Promoter methylation of p16 and RASSF1A genes may contribute to the risk of papillary thyroid cancer: A meta-analysis

Jiang,Jia‑Li; Tian,Gui‑Lan; Chen,Shu‑Jiao; Xu,Li; Wang,Hui‑Qin

doi:10.3892/etm.2015.2656

Promoter methylation of p16 and RASSF1A genes may contribute to the risk of papillary thyroid cancer: A meta-analysis

Authors:
- Jia‑Li Jiang
- Gui‑Lan Tian
- Shu‑Jiao Chen
- Li Xu
- Hui‑Qin Wang
View Affiliations

Affiliations: Department of Clinical Laboratory, Zaozhuang Municipal Hospital, Zaozhuang, Shandong 277000, P.R. China, Department of Obstetrics and Gynecology, Center Hospital of Xiji Town, Zaozhuang, Shandong 277200, P.R. China, Department of Clinical Laboratory, Blood Center of Zaozhuang, Zaozhuang, Shandong 277000, P.R. China
Published online on: July 24, 2015 https://doi.org/10.3892/etm.2015.2656
Pages: 1549-1555

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present meta-analysis was to investigate the correlation of promoter methylation of the p16 and Ras association domain family 1 isoform A (RASSF1A) genes with the risk of the development of papillary thyroid cancer (PTC). A number of electronic databases were searched without language restrictions as follows: Medline (1966‑2013), the Cochrane Library database (Issue 12, 2013), Embase (1980‑2013), CINAHL (1982‑2013), Web of Science (1945‑2013) and the Chinese Biomedical Database (CBM; 1982‑2013). A meta‑analysis was performed with the use of Stata statistical software. The odds ratios (ORs), ratio differences (RDs) and 95% confidence intervals (95% CIs) were calculated. In the present meta‑analysis, eleven clinical cohort studies with a total of 734 patients with PTC were included. The results of the current meta‑analysis indicated that the frequency of promoter methylation of p16 in cancer tissues was significantly higher compared with that in normal, adjacent and benign tissues (cancer tissues vs. normal tissues: OR=7.14; 95% CI, 3.30‑15.47; P<0.001; cancer tissues vs. adjacent tissues: OR=11.90; 95% CI, 5.55‑25.52; P<0.001; cancer tissues vs. benign tissues: OR=2.25; 95% CI, 1.67‑3.03; P<0.001, respectively). The results also suggest that RASSF1A promoter methylation may be implicated in the pathogenesis of PTC (cancer tissues vs. normal tissues: RD=0.53; 95% CI, 0.42‑0.64; P<0.001; cancer tissues vs. adjacent tissues: RD=0.39; 95% CI, 0.31‑0.48; P<0.001; cancer tissues vs. benign tissues: RD=0.39; 95% CI, 0.31‑0.47; P<0.001; respectively). Thus, the present meta‑analysis indicates that aberrant promoter methylation of p16 and RASSF1A genes may play a crucial role in the pathogenesis of PTC.

View Figures

View References

1	Sipos JA and Mazzaferri EL: Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol). 22:395–404. 2010. View Article : Google Scholar : PubMed/NCBI
2	Swierniak M, Wojcicka A, Czetwertynska M, et al: In-depth characterization of the microRNA transcriptome in normal thyroid and papillary thyroid carcinoma. J Clin Endocrinol Metab. 98:E1401–E1409. 2013. View Article : Google Scholar : PubMed/NCBI
3	Jonklaas J, NoguerasGonzalez G, Munsell M, et al: The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab. 97:E878–E887. 2012. View Article : Google Scholar : PubMed/NCBI
4	LiVolsi VA: Papillary thyroid carcinoma: an update. Mod Pathol. 24 (Suppl 2):S1–S9. 2011. View Article : Google Scholar : PubMed/NCBI
5	Hughes DT, Haymart MR, Miller BS, Gauger PG and Doherty GM: The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid. 21:231–236. 2011. View Article : Google Scholar : PubMed/NCBI
6	Enewold L, Zhu K, Ron E, et al: Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev. 18:784–791. 2009. View Article : Google Scholar : PubMed/NCBI
7	Detours V, Delys L, Libert F, et al: Genome-wide gene expression profiling suggests distinct radiation susceptibilities in sporadic and post-Chernobyl papillary thyroid cancers. Br J Cancer. 97:818–825. 2007. View Article : Google Scholar : PubMed/NCBI
8	Xing M: Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol. 321:86–93. 2010. View Article : Google Scholar : PubMed/NCBI
9	Mohammadiasl J, Larijani B, Khorgami Z, et al: Qualitative and quantitative promoter hypermethylation patterns of the p16, TSHR, RASSF1A and RARβ2 genes in papillary thyroid carcinoma. Med Oncol. 28:1123–1128. 2011. View Article : Google Scholar : PubMed/NCBI
10	Kunstman JW, Korah R, Healy JM, Prasad M and Carling T: Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma. Surgery. 154:1255–1261. 2013. View Article : Google Scholar : PubMed/NCBI
11	AbouZeid AA, Azzam AZ and Kamel NA: Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer. Scand J Clin Lab Invest. 71:542–547. 2011. View Article : Google Scholar : PubMed/NCBI
12	Shidham VB, Mehrotra R, Varsegi G, et al: p16^INK4a immunocytochemistry on cell blocks as an adjunct to cervical cytology: Potential reflex testing on specially prepared cell blocks from residual liquid-based cytology specimens. Cytojournal. 8:12011. View Article : Google Scholar : PubMed/NCBI
13	LutfulKabir FM, Agarwal P, Deinnocentes P, et al: Novel frameshift mutation in the p16/INK4A tumor suppressor gene in canine breast cancer alters expression from the p16/INK4A/p14ARF locus. J Cell Biochem. 114:56–66. 2013. View Article : Google Scholar : PubMed/NCBI
14	Rabien A, SanchezRuderisch H, Schulz P, et al: Tumor suppressor p16 INK4a controls oncogenic K-Ras function in human pancreatic cancer cells. Cancer Sci. 103:169–175. 2012. View Article : Google Scholar : PubMed/NCBI
15	Kamb A, ShattuckEidens D, Eeles R, et al: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet. 8:23–26. 1994. View Article : Google Scholar : PubMed/NCBI
16	Wang P, Pei R, Lu Z, Rao X and Liu B: Methylation of p16 CpG islands correlated with metastasis and aggressiveness in papillary thyroid carcinoma. J Chin Med Assoc. 76:135–139. 2013. View Article : Google Scholar : PubMed/NCBI
17	Tian Y, Hou Y, Zhou X, Cheng H and Zhou R: Tumor suppressor RASSF1A promoter: p53 binding and methylation. PLoS One. 6:e170172011. View Article : Google Scholar : PubMed/NCBI
18	CunhaDda S, Simões MI, Viviani DN, et al: Carotid artery rupture following radioiodine therapy for differentiated thyroid carcinoma. Arq Bras Endocrinol Metabol. 55:419–425. 2011. View Article : Google Scholar : PubMed/NCBI
19	Gao T, Wang S, He B, et al: The association of RAS association domain family Protein1A (RASSF1A) methylation states and bladder cancer risk: a systematic review and meta-analysis. PLoS One. 7:e483002012. View Article : Google Scholar : PubMed/NCBI
20	Dreijerink K, Braga E, Kuzmin I, et al: The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci USA. 98:7504–7509. 2001. View Article : Google Scholar : PubMed/NCBI
21	Yee KS, Grochola L, Hamilton G, et al: A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcoma. Cancer Res. 72:2206–2217. 2012. View Article : Google Scholar : PubMed/NCBI
22	Nakamura N, Carney JA, Jin L, et al: RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. Lab Invest. 85:1065–1075. 2005. View Article : Google Scholar : PubMed/NCBI
23	Dammann R, Schagdarsurengin U, Seidel C, et al: The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol. 20:645–663. 2005.PubMed/NCBI
24	vanVlodrop IJ, Niessen HE, Derks S, et al: Analysis of promoter CpG island hypermethylation in cancer: location, location, location! Clin Cancer Res. 17:4225–4231. 2011. View Article : Google Scholar : PubMed/NCBI
25	Santoro A, Pannone G, Carosi MA, et al: BRAF mutation and RASSF1A expression in thyroid carcinoma of southern Italy. J Cell Biochem. 114:1174–1182. 2013. View Article : Google Scholar : PubMed/NCBI
26	Huang P, Li DX and Zhang Y: Methylation of p16 gene and expression of p16 protein in human thyroid neoplasms. J Practical Oncol. 21:49–51. 2006.(In Chinese).
27	Schagdarsurengin U, Gimm O, HoangVu C, et al: Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res. 62:3698–3701. 2002.PubMed/NCBI
28	Stang A: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI
29	Zintzaras E and Ioannidis JP: HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics. 21:3672–3673. 2005. View Article : Google Scholar : PubMed/NCBI
30	Peters JL, Sutton AJ, Jones DR, Abrams KR and Rushton L: Comparison of two methods to detect publication bias in meta-analysis. JAMA. 295:676–680. 2006. View Article : Google Scholar : PubMed/NCBI
31	Dai YL, Zhang F, Jiang ZR, et al: Association the methylation of p16 and RASSF1A with papillary thyroid carcinoma. Chin J Int Med. 50:428–429. 2011.
32	Li XF, Jin YL, He ZL and Gu DK: Detecting the abnormal methylation of plasma p16 promoter in patients with thyroid carcinoma by nested-methylation-specific polymerase chain reaction. Chin J Prev Contr Chronic Dis. 21:34–36. 2013.(In Chinese).
33	Peng ZL, Cao RX, Wen GB, Liu JH and Wen F: The methylation of p16 gene in papillary thyroid carcinoma. J Mod Oncol. 14:1501–1503. 2006.(In Chinese).
34	Qu F and Xue WJ: RASSF1A methylation and its clinical roles in papillary thyroid carcinoma. J Nantong Univ (Med Sci). 32:490–492. 2012.(In Chinese).
35	Tang JD and Su XL: Research of CpG island methylation status of NIS and RASSF1A gene promoters in papillary thyroid carcinomas. China J Mod Med. 20:3282–3285. 2010.(In Chinese).
36	Wang C, Shi JH and Wang WY: Expressions of p53 and p16 and their clinical significance in thyroid papillary carcinoma. J Bengbu Med Col. 34:871–873. 2009.(In Chinese).
37	Wang XH, Zhang GC, Liu YL, et al: Detecting the abnormal methylation of RASSF1A in patients with thyroid carcinoma. Shaanxi Med J. 38:790–792. 2009.(In Chinese).
38	Barroeta JE, Baloch ZW, Lal P, et al: Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr Pathol. 17:225–234. 2006. View Article : Google Scholar : PubMed/NCBI
39	Lam AK, Lo CY, Leung P, et al: Clinicopathological roles of alterations of tumor suppressor gene p16 in papillary thyroid carcinoma. Ann Surg Oncol. 14:1772–1779. 2007. View Article : Google Scholar : PubMed/NCBI
40	Boltze C, Zack S, Quednow C, et al: Hypermethylation of the CDKN2/p16INK4A promotor in thyroid carcinogenesis. Pathol Res Pract. 199:399–404. 2003. View Article : Google Scholar : PubMed/NCBI
41	Xing M, Cohen Y, Mambo E, et al: Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res. 64:1664–1668. 2004. View Article : Google Scholar : PubMed/NCBI
42	Fernandes MS, Carneiro F, Oliveira C and Seruca R: Colorectal cancer and RASSF family - a special emphasis on RASSF1A. Int J Cancer. 132:251–258. 2013. View Article : Google Scholar : PubMed/NCBI